PTC THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $5.66B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $272.55M | $-0.03 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $211.00M | $0.20 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 25, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| GAAP R&D and SG&A expenseGAAP | Full-Year 2026 | $775.00M to $815.00M | Maintained |
| Non-GAAP R&D and SG&A expensenon-GAAP | Full-Year 2026 | $680.00M to $720.00M | Maintained |
| Expected total revenue | Full-Year 2026 | $1.18B to $1.28B | Raised |
| t otal product revenue | Full-Year 2026 | $850.00M to $950.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Ptc Therapeutics filed with the SEC
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Announces Pricing of Convertible
Other events · EX-99.1 to Form 8-K
PTC Therapeutics Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
Regulation FD disclosure · EX-99.1 to Form 8-K
PIVOT-HD LTE 24-Month Interim Analysis Results
Regulation FD disclosure · EX-99.2 to Form 8-K
PTC Therapeutics Appoints Biotech Banking Pioneer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Regulatory Update on Translarna™
Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
J.P. Morgan 2026 Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PTC Therapeutics Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC518 PIVOT-HD Study Achieves Primary Endpoint
Regulation FD disclosure · EX-99.1 to Form 8-K
PIVOT-HD Phase 2 Readout 1
Regulation FD disclosure · EX-99.2 to Form 8-K
PTC Therapeutics Provides Regulatory Update
Regulation FD disclosure · EX-99.1 to Form 8-K
refusing the renewal of the conditional marketing authorisation for the medicinal
Regulation FD disclosure · EX-99.2 to Form 8-K
PTC Therapeutics Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43 rd Annual J.P. Morgan Healthcare Conference
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pam and Kelsey living with PKU
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington’s Disease Program
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Enters into Agreement to Sell
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CHMP Maintains Negative Opinion on Translarna™ Reexamination
Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CHMP Issues Negative Opinion on Translarna™ Following
Regulation FD disclosure · EX-99.1 to Form 8-K
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington’s Disease Patients
Material agreement · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
PIVOT-HD Data Update – Q2 2024
Material agreement · Shareholder vote results · Regulation FD disclosure · EX-99.2 to Form 8-K
PTC Therapeutics Announces European Commission Returns Translarna™
Regulation FD disclosure · EX-99 to Form 8-K
PTC Therapeutics Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics – JP Morgan 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PTC Therapeutics Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
PTC Therapeutics Announces Evrysdi ® Royalty Agreement
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K